Indaptus Therapeutics, Inc. (NASDAQ:INDP – Get Rating) was the recipient of a significant decrease in short interest during the month of July. As of July 31st, there was short interest totalling 57,500 shares, a decrease of 25.3% from the July 15th total of 77,000 shares. Currently, 1.1% of the company's shares are short sold. Based on an average daily volume of 469,900 shares, the short-interest ratio is currently 0.1 days.

Insider Transactions at Indaptus Therapeutics

In related news, CEO Jeffrey A. Meckler purchased 19,727 shares of the business's stock in a transaction dated Monday, June 6th. The shares were purchased at an average cost of $2.63 per share, for a total transaction of $51,882.01. Following the completion of the acquisition, the chief executive officer now owns 45,374 shares in the company, valued at approximately $119,333.62. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 36.00% of the company's stock.

Institutional Trading of Indaptus Therapeutics

A number of hedge funds have recently added to or reduced their stakes in INDP. Northern Trust Corp purchased a new stake in Indaptus Therapeutics in the first quarter worth about $41,000. Renaissance Technologies LLC purchased a new stake in Indaptus Therapeutics in the second quarter worth about $51,000. State Street Corp purchased a new stake in Indaptus Therapeutics in the first quarter worth about $78,000. Investment House LLC lifted its stake in Indaptus Therapeutics by 272.8% in the fourth quarter. Investment House LLC now owns 95,629 shares of the company's stock worth $545,000 after acquiring an additional 69,976 shares during the period. Finally, Vanguard Group Inc. lifted its stake in Indaptus Therapeutics by 18.7% in the first quarter. Vanguard Group Inc. now owns 242,235 shares of the company's stock worth $969,000 after acquiring an additional 38,216 shares during the period. 22.26% of the stock is owned by hedge funds and other institutional investors.

Indaptus Therapeutics Stock Performance

Indaptus Therapeutics (NASDAQ:INDP – Get Rating) last released its quarterly earnings data on Thursday, May 12th. The company reported ($0.41) earnings per share for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.02). As a group, equities research analysts expect that Indaptus Therapeutics will post -1.85 earnings per share for the current year.

Indaptus Therapeutics Company Profile

(Get Rating)

Indaptus Therapeutics, Inc, a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial.

See Also

• Get a free copy of the StockNews.com research report on Indaptus Therapeutics (INDP)
• 2 Important Retail Stock Battles to Watch
• MarketBeat: Week in Review 8/8 – 8/12
• What Is WallStreetBets and What Stocks Are They Targeting?
• Institutions And Analysts Propel Jack In The Box Higher
• Can You Guess Which EV Stock Is Beating Tesla ?

Receive News & Ratings for Indaptus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indaptus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.